Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Retained Earnings: 2009-2024

Historic Retained Earnings for Madrigal Pharmaceuticals (MDGL) over the last 12 years, with Dec 2024 value amounting to -$1.8 billion.

  • Madrigal Pharmaceuticals' Retained Earnings fell 16.59% to -$2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 billion, marking a year-over-year decrease of 16.59%. This contributed to the annual value of -$1.8 billion for FY2024, which is 34.86% down from last year.
  • Madrigal Pharmaceuticals' Retained Earnings amounted to -$1.8 billion in FY2024, which was down 34.86% from -$1.3 billion recorded in FY2023.
  • Madrigal Pharmaceuticals' Retained Earnings' 5-year high stood at -$425.5 million during FY2020, with a 5-year trough of -$1.8 billion in FY2024.
  • Over the past 3 years, Madrigal Pharmaceuticals' median Retained Earnings value was -$1.3 billion (recorded in 2023), while the average stood at -$1.4 billion.
  • Data for Madrigal Pharmaceuticals' Retained Earnings shows a maximum YoY slumped of 90.62% (in 2020) over the last 5 years.
  • Over the past 5 years, Madrigal Pharmaceuticals' Retained Earnings (Yearly) stood at -$425.5 million in 2020, then plummeted by 56.83% to -$667.3 million in 2021, then slumped by 44.27% to -$962.7 million in 2022, then crashed by 38.81% to -$1.3 billion in 2023, then tumbled by 34.86% to -$1.8 billion in 2024.